The Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Among Patients with Intrahepatic Cholangiocarcinoma by Buettner, S et al.
Surgery 164 (2018) 411–418 
Contents lists available at ScienceDirect 
Surgery 
journal homepage: www.elsevier.com/locate/surg 
Liver 
Presented at the Academic Surgical Congress 2018 
The impact of neutrophil-to-lymphocyte ratio and 
platelet-to-lymphocyte ratio among patients with intrahepatic 
cholangiocarcinoma ✩ 
Stefan Buettner a , Gaya Spolverato, MD b , Charles W. Kimbrough, MD, MPH b , 
Sorin Alexandrescu, MD c , Hugo P. Marques, MD d , Jorge Lamelas, MD d , 
Luca Aldrighetti, MD e , T. Clark Gamblin, MD f , Shishir K. Maithel, MD g , 
Carlo Pulitano, MD h , Matthew Weiss, MD i , Todd W. Bauer, MD j , Feng Shen, MD k , 
George A. Poultsides, MD l , J. Wallis Marsh, MD m , Jan N.M. IJzermans, MD, PhD a , 
Bas Groot Koerkamp, MD, PhD a , Timothy M. Pawlik, MD, MPH, PhD b , ∗
a Erasmus MC University Medical Center, Rotterdam, Netherlands; 
b Ohio State University Wexner Medical Center, Columbus, OH 
c Fundeni Clinical Institute, Bucharest, Romania 
d Curry Cabral Hospital, Lisbon, Portugal 
e Ospedale San Raffaele, Milan, Italy 
f Medical College of Wisconsin, Milwaukee, WI 
g Emory University, Atlanta, GA 
h University of Sydney, Australia 
i Johns Hopkins Hospital, Baltimore, MD 
j University of Virginia, Charlottesville, VA 
k Eastern Hepatobiliary Surgery Hospital, Shanghai, China 
l Stanford University, Stanford, CA 
m University of Pittsburgh Medical Center, Pittsburgh, PA 
a r t i c l e i n f o 
Article history: 
Accepted 2 May 2018 
Available online 11 June 2018 
a b s t r a c t 
Background: Neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio may be host factors as- 
sociated with prognosis. We sought to determine whether neutrophil-to-lymphocyte and platelets-to- 
lymphocyte ratio were associated with overall survival among patients undergoing surgery for intrahep- 
atic cholangiocarcinoma. 
Methods: Patients who underwent resection for intrahepatic cholangiocarcinoma between 1990 and 2015 
were identiﬁed from 12 major centers. Clinicopathologic factors and overall survival were compared 
among patients stratiﬁed by neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio. Risk fac- 
tors identiﬁed on multivariable analysis were included in a prognostic model and the discrimination was 
assessed using Harrell’s concordance index (C index). 
Results: A total of 991 patients were identiﬁed. Median neutrophil-to-lymphocyte ratio and platelets-to- 
lymphocyte ratio were 2.7 (interquartile range [IQR]: 2.0–4.0) and 109.6 (IQR: 72.4–158.8), respectively. 
Preoperative neutrophil-to-lymphocyte ratio was elevated ( ≥5) in 100 patients (10.0%) and preoperative 
platelets-to-lymphocyte ratio ( ≥190) in 94 patients (15.2%). Patients with low and high neutrophil-to- 
lymphocyte ratio and platelets-to-lymphocyte ratio generally had similar baseline characteristics with re- 
gard to tumor characteristics. Overall survival was 37.7 months (95% conﬁdence interval [CI]: 32.7–42.6); 
1-, 3-, and 5-year overall survival was 78.8%, 51.6%, and 39.3%, respectively. Patients with an neutrophil- 
to-lymphocyte ratio < 5 had a median survival of 47.1 months (95% CI: 37.9–53.3) compared with a 
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[  Introduction 
Intrahepatic cholangiocarcinoma (ICC) is the second most com-
mon primary liver malignancy, with an incidence of approximately
1–2 per 10 0,0 0 0 persons. 1–3 Complete surgical resection remains
the only option for cure, yet only a minority of patients (15%)
present with resectable disease at the time of diagnosis. 4 Progno-
sis is generally dismal even after curative-intent surgery, with a
median survival ranging from 24 to 36 months. 5–9 As such, bet-
ter tools to predict long-term prognosis after ICC resection may
help to improve preoperative patient selection, as well as to iden-
tify which patients might beneﬁt the most from a multidisciplinary
approach. 5 
To date, no prognostic staging system or nomogram has had
excellent prognostic discrimination among patients with ICC. 10 In
addition, most prognostic models are based on pathologic fac-
tors only available after surgery, and few models have attempted
to estimate long-term prognosis based on factors available be-
fore ICC resection. 11–14 To improve the predictive ability of prog-
nostic models for ICC, some authors have proposed to use tumor
biomarkers as a surrogate for tumor biology. The most common
tumor biomarkers associated with hepatopancreatobiliary diseases
are carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA
19-9), yet data on the correlation of these markers with clini-
cal outcomes have been discordant. 15,16 Other non–tumor-speciﬁc
biomarkers, including neutrophil-to-lymphocyte ratio (NLR) and
platelet-to-lymphocyte ratio (PLR), have recently been suggested
to be correlated with prognosis. 17–19 Rather than being associated
with the primary tumor, NLR and PLR reﬂect the host response to
the underlying malignancy. NLR and PLR are linked to the preoper-
ative host inﬂammatory response to the tumor and therefore may
facilitate estimation of long-term prognosis before surgery. NLR
and PLR have been associated with poor survival among patients
with several different types of cancers yet have not been examined
relative to ICC prognosis. 20–25 
Therefore, the objective of the present study was to deﬁne
the prognostic impact of NLR and PLR among patients undergoing
curative-intent resection for ICC. Furthermore, we sought to exam-
ine the relative change in predicting long-term prognosis with the
addition of NLR and PLR to other established risk factors for ICC. 
Methods 
All patients undergoing curative-intent resection for ICC with
available follow-up between January 1, 1990, and July 1, 2016 were
identiﬁed from one of 12 participating major hepatobiliary institu-
tions in the United States, Asia, Australia, and Europe (Johns Hop-
kins University, Baltimore, Maryland; Emory University, Atlanta,
Georgia; Stanford University Medical Center, Stanford, California;
University of Virginia Health System, Charlottesville, Virginia;
Fundeni Clinical Institute, Bucharest, Romania; Beaujon Hospital,s (95% CI: 4.8–39.1) among patients with an neutrophil-to-lymphocyte
, patients who had a platelets-to-lymphocyte ratio < 190 vs platelets-to-
mparable long-term survival ( P > .05). On multivariable analysis, an ele-
 ratio was independently associated with decreased overall survival (haz-
7; P = .002). Patients could be stratiﬁed into low- versus high-risk groups
ﬁc factors such as lymph node status, tumor size, number, and vascular
 neutrophil-to-lymphocyte ratio was added to the prognostic model, the
del improved (C index 0.71). 
il-to-lymphocyte ratio was independently associated with worse overall
nostic estimation of long-term survival among patients with intrahepatic
 resection. 
© 2018 Elsevier Inc. All rights reserved.
lichy, France; Curry Cabral Hospital, Lisbon, Portugal; Eastern
epatobiliary Surgery Hospital, Shanghai, China; Ottawa General
ospital, Ottawa, Canada; Royal Prince Alfred Hospital, Sydney,
ustralia; San Raffaele Hospital, Milan, Italy; Erasmus University
edical Centre Rotterdam, the Netherlands). Only patients under-
oing surgery for histologically conﬁrmed ICC were included in the
tudy population; patients who did not undergo resection, as well
s patients who underwent transplantation or received preopera-
ive chemotherapy, were excluded. The respective Institutional Re-
iew Boards of each participating institution approved this study. 
Demographic and clinical data were collected, including age,
ex, American Society of Anesthesiologists class, serum CEA and
A 19-9, presence of jaundice, history of hepatitis B or C, and
resence of cirrhosis. Pathologic data such as tumor number,
ize, major vascular invasion, presence of extrahepatic disease,
orphologic type, histologic grade, presence of nodal metastases,
nal resection margin, and presence of vascular and/or perineural
nvasion were also included. Data on treatment-related variables,
uch as type of surgery and lymphadenectomy, were recorded.
 minor hepatectomy was deﬁned as a hepatic resection of less
han 3 Couinaud segments. Margin status was categorized as
0 for microscopically negative resection margins and R1 for
icroscopically positive margins. 
Data on short- and long-term outcomes were collected. Short-
erm outcomes included duration of hospital stay as well as post-
perative morbidity and mortality. The date of last follow-up and
ital status were also collected on all patients. Mortality was cal-
ulated from the date of index operation. Long-term outcome, such
s overall survival (OS), was stratiﬁed based on NLR and PLR. NLR
nd PLR were calculated by dividing the absolute number of neu-
rophils or platelets by the absolute number of lymphocytes. For
oth the univariable analysis and the predictive model, the previ-
usly validated cutoff of 5 was used for NLR and 190 for PLR. 22 
tatistical analysis 
Summary statistics were provided as whole numbers and per-
entages for categorical variables and medians with interquartile
ange (IQR) for continuous variables. The primary outcome of in-
erest was OS, deﬁned as the time interval between the date of
urgery and the date of death or last follow-up, as appropriate.
stimates for OS were calculated using the Kaplan-Meier method.
ifferences in OS were assessed using the log rank test. Multi-
le imputations were performed to account for missing values. A
ultivariable Cox proportional hazards model was used to identify
otential risk factors. Backward selection was used to select fac-
ors for the multivariable analysis and factors with a signiﬁcance
evel < .05 remained in the regression model. Results from the Cox
odels were reported as hazard ratios (HRs) and corresponding
5% conﬁdence intervals (CIs). Linear predictors (log-hazard ratios
logHR]) of the risk factors included into the multivariable analysis
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Table I 
Baseline characteristics of the validation cohort ( n = 991). 
Variable n (%)/Median (IQR) 
Gender 
Male 536 (54.1) 
Female 454 (45.9) 
Age, y 59 (50–67) 
ASA 
I 99 (11.1) 
II 462 (51.9) 
III 259 (29.1) 
IV/V 69 (7.7) 
BMI 25.4 (22.5–28.2) 
Hepatitis B 196 (23.6) 
Hepatitis C 20 (2.4) 
Cirrhosis 107 (13.0) 
Preoperative suspicious lymph nodes 167 (19.5) 
Period of treatment 
1990–20 0 0 35 (3.5 
20 01–20 05 114 (11.5) 
2006–2010 414 (41.8) 
2011–2016 428 (43.2) 
No. of tumors 1 (1-1) 
Bilobar location 191 (19.4) 
Tumor size (cm) 6.0 (4.3–9.0) 
Major vascular invasion 92 (9.3) 
Extrahepatic disease 25 (2.5) 
Serum GGT 78.0 (45.8–117.5) 
Serum CA 19-9 52.1 (17.8–220.0) 
Serum CEA 2.4 (1.4–4.1) 
Serum total bilirubin 5.8 (3.3–10.1) 
Preoperative jaundice 96 (9.7) 
Neutrophil-to-lymphocyte ratio 2.7 (2.0–4.0) 
Platelet-to-lymphocyte ratio 109.6 (72.4–158.8) 
ASA , American Society of Anesthesiologists; BMI , body mass in- 
dex; CA , cancer antigen; CEA , carcinoembryonic antigen; GGT , 





































l  ere used to classify patients into in low- and high-risk groups.
he discrimination of the model was assessed using Harrell’s con-
ordance index (C index). All analyses were performed using SPSSTable II 
Postoperative results by neutrophil-to-lymphocyte ratio. 
Variable Total ( n = 991) 
Neutrophil-to-lymphocyte ratio (NLR) 2.7 (2.0-4.0) 
Platelet-to-lymphocyte ratio (PLR) 109.6 (72.4-158.8
Type of resection 
Minor hepatectomy ( < 3 segments) 408 (41.5) 
Right hepatectomy 156 (15.9) 
Left hepatectomy 185 (18.8) 
Extended right hepatectomy 123 (12.5) 
Extended left hepatectomy 92 (9.3) 
Central hepatectomy 20 (2.0) 
Morphologic type 
Mass-forming 804 (86.6) 
Papillary 28 (3.0) 
Periductal inﬁltrating 43 (4.6) 
Mass-forming and periductal inﬁltrating 53 (5.7) 
Microvascular invasion 244 (25.2) 
Perineural invasion 142 (15.9) 
Invasion of adjacent organs 73 (7.4) 
Satellite lesions 764 (77.3) 
Intrahepatic metastases 68 (6.9) 
Lymphadenectomy 4 43 (4 4.8) 
Lymph node metastases 170 (17.2) 
Margin status 
R0 856 (87.2) 
R1 125 (12.7) 
Postoperative complication 393 (39.8) 
Duration of stay, days 12 (7–17) 
Readmission within 30 days 45 (4.5) 
Postoperative mortality 33 (3.7) 2.0 (IBM Corp, Armonk, NY) and the mice and rms package for R
.3.3 ( https://cran.r-project.org/ ). All tests were 2-sided. 
esults 
atient characteristics 
Overall 991 patients were eligible for curative-intent resection
n the participating centers and met the inclusion criteria; 536
54.1%) were male and the median patient age was 59 years (IQR:
0–67) ( Table I ). Most patients were American Society of Anesthe-
iologists class II or III ( n = 721; 81%). One out of ten patients had
irrhosis ( n = 107; 13%) and one quarter of patients had either hep-
titis B or C (hepatitis B, n = 196, 23.6%; hepatitis C, n = 20, 2.4%).
uspicious lymph nodes were detected on preoperative imaging in
67 (19.5%) patients. Average tumor size was 6.0 cm (IQR: 4.3–9.0),
nd most patients had a single tumor (IQR: 1–1) that was limited
o one hemi-liver ( n = 796; 80.6%). The most common morpho-
ogic type was mass forming ( n = 804, 86.6%), whereas papillary
as the least common ( n = 28, 3%). A large majority of the oper-
tions were conducted within the last decade ( n = 842; 85%) and
nvolved a major hepatectomy ( n = 583, 58.5%) ( Table II ). At the
ime of surgery, a lymphadenectomy was performed in 44.8% of
atients ( n = 443). Lymph node metastasis occurred in 170 patients
17.2%) and major vascular invasion in 92 patients (9.3%), and 25
atients (2.5%) had extrahepatic disease. On ﬁnal pathologic exam-
nation, the majority of patients had microscopically negative mar-
ins (R0, n = 856, 87.2%). A postoperative complication occurred in
93 patients (39.8%), and 33 patients (3.7%) died within 90 days of
urgery. Median duration of stay was 12 days (IQR: 7–17). 
Median NLR and PLR were 2.7 (IQR: 2.0–4.0) and 109.6 (IQR:
2.4–158.8), respectively. The correlation of clinicopathologic char-
cteristics and operative details with NLR and PLR are noted
n Table II . Preoperative NLR was elevated ( ≥5) in 100 patients
10.0%) and preoperative PLR ( ≥190) in 94 patients (15.2%). Pa-
ients with low and high NLR and PLR generally had similar base-
ine characteristics with regard to performance status and tumorNLR < 5 ( n = 568) NLR ≥5 ( n = 100) P 
2.5 (2.0–3.3) 8.4 (6.2–13.3) < .001 
) 103.8 (69.1–140.6) 206.7 (143.6–261.9) < .001 
.573 
287 (50.5) 46 (46.5) 
74 (13.0) 11 (11.1) 
98 (17.3) 17 (17.2) 
58 (10.2) 10 (10.1) 
43 (7.6) 13 (13.1) 
8 (1.4) 2 (2.0) 
.035 
483 (88.3) 75 (82.4) 
20 (3.7) 2 (2.2) 
19 (3.5) 3 (3.3) 
25 (4.6) 11 (12.1) 
118 (21.0) 19 (20.0) .825 
70 (13.1) 8 (9.2) .304 
39 (6.9) 13 (13.3) .030 
136 (23.9) 19 (19.0) .280 
38 (6.7) 5 (5.0) .523 
217 (38.3) 53 (53.0) .006 
91 (16.0) 16 (16.0) .996 
.559 
518 (91.7) 89 (89.9) 
47 (8.3) 10 (10.1) 
196 (34.5) 39 (39.4) .348 
13 (8–17) 14 (11–21) .002 
16 (3.3) 6 (7.5) .075 
16 (3.0) 5 (5.4) .239 
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Table III 
Postoperative results by platelet-to-lymphocyte ratio. 
Variable Total ( n = 991) PLR < 190 ( n = 562) PLR ≥ 190 ( n = 94) P 
Neutrophil-to-lymphocyte ratio (NLR) 2.7 (2.0–4.0) 2.5 (1.9–3.4) 5.2 (3.6–8.4) < .001 
Platelet-to-lymphocyte ratio (PLR) 109.6 (72.4–158.8) 100.0 (63.0–133.0) 250.1 (218.0–292.2) < .001 
Type of resection .472 
Minor hepatectomy ( < 3 segments) 408 (41.5) 271 (51.5) 39 (41.9) 
Right hepatectomy 156 (15.9) 62 (11.8) 16 (17.2) 
Left hepatectomy 185 (18.8) 91 (17.3) 16 (17.2) 
Extended right hepatectomy 123 (12.5) 51 (9.7) 12 (12.9) 
Extended left hepatectomy 92 (9.3) 42 (8.0) 9 (9.7) 
Central hepatectomy 20 (2.0) 9 (1.7) 1 (1.1) 
Morphologic type .783 
Mass-forming 804 (86.6) 456 (89.4) 73 (91.2) 
Papillary 28 (3.0) 17 (3.3) 2 (2.5) 
Periductal inﬁltrating 43 (4.6) 14 (2.7) 3 (3.8) 
Mass-forming and periductal inﬁltrating 53 (5.7) 23 (4.5) 2 (2.5) 
Microvascular invasion 244 (25.2) 110 (21.1) 24 (27.3) .197 
Perineural invasion 142 (15.9) 63 (12.7) 15 (19.7) .096 
Invasion of adjacent organs 73 (7.4) 27 (5.2) 9 (9.7) .086 
Satellite lesions 764 (77.3) 123 (23.4) 17 (18.1) .258 
Intrahepatic metastases 68 (6.9) 36 (6.9) 4 (4.3) .345 
Lymphadenectomy 4 43 (4 4.8) 200 (38.1) 46 (48.9) .048 
Lymph node metastases 170 (17.2) 78 (14.8) 12 (12.8) .601 
Margin status .020 
R0 856 (87.2) 483 (92.4) 79 (84.9) 
R1 125 (12.7) 40 (7.6) 14 (15.1) 
Postoperative complication 393 (39.8) 179 (34.1) 40 (42.6) .114 
Duration of stay, days 12 (7–17) 13 (8–17) 12 (9–17) .733 
Readmission within 30 days 45 (4.5) 14 (3.0) 8 (8.7) .011 




































































n  characteristics ( Tables II and III ). In particular, there was no differ-
ence in the incidence of liver disease between high- and low-PLR
groups; there was also no difference in the NLR groups. No pa-
tient in the present study had portal hypertension/hypersplenism
or signs of frank cirrhosis. Few differences were noted among pa-
tients with NLR < 5 and NLR ≥5 ( Table II ). Patients with NLR ≥5
were more likely to have invasion of adjacent organs (13.3% vs
6.9%; P = .030) and a prolonged duration of stay (14, IQR: 11–21
vs 13, IQR: 8-17; P = .002). Lymphadenectomy was also more com-
monly performed among patients with NLR ≥5 (53.0% vs 38.3%;
P = .006). There were similarly few differences among patients
with PLR < 190 vs PLR ≥190 ( Table III ). Patients with PLR ≥190
were, however, more likely to have had a lymphadenectomy (48.9%
vs 38.1%, P = .048) and were more likely to have had a resection
with microscopically positive margins (R1; 15.1% vs 7.6%, P = .020). 
Long-term outcome 
Within a median follow-up of 29 months, OS was 37.7 months
(95% CI: 32.7–42.6); 1-, 3-, and 5-year OS was 78.8%, 51.6%, and
39.3%, respectively. Patients with an NLR < 5 had a median sur-
vival of 47.1 months (95% CI: 37.9–53.3) compared with a median
survival of 21.9 months (95% CI: 4.8–39.1) among patients with
an NLR ≥5 ( P = .001; Fig. 1 ). In contrast, patients who had a PLR
< 190 vs PLR ≥190 had comparable long-term survival ( P > .05;
Fig. 2 ). On the univariable analysis, several factors were associ-
ated with OS, including preoperative suspicious lymph nodes, tu-
mor size, number of lesions, vascular invasion, preoperative jaun-
dice, extrahepatic disease, and NLR. On the multivariable analysis,
after controlling for competing risk factors, lymph node metastases
(HR: 1.38, 95% CI: 1.10–1.74; P = .006), tumor size (HR: 1.04, 95% CI:
1.02–1.07; P < .001), number of lesions (HR: 1.15, 95% CI: 108–1.24;
P < .001), major vascular invasion (HR: 1.38, 95% CI: 1.03–1.85;
P = .030), preoperative jaundice (HR: 1.58, 95% CI: 1.20–2.08; P <
.001), extrahepatic disease (HR: 2.32, 95% CI: 1.01–1.07; P = .001),
and preoperative serum CEA level (HR: 1.00, 95% CI: 1.00–1.00; P
< .012) remained as independent predictors of OS ( Table IV ). Inddition, after backward selection of predictors of survival, NLR
emained an independent risk factor of OS in the multivariable
odel (HR: 1.04, 95% CI: 1.01–1.07; P = .002). Of note, additional
nalyses revealed that there was no “dose effect” of NLR on prog-
osis. 
OS was worse among patients who had any one of the risk fac-
ors identiﬁed on multivariable analysis: suspicious lymph nodes
logHR 3 ×10 –1 ), CEA > 3 ng/mL (logHR 2 ×10 –1 ), preoperative
aundice (logHR 5 ×10 –1 ), tumor size > 6 cm (logHR 4 ×10 –1 ), 2–3
umors (logHR 3 ×10 –1 ), > 3 tumors (logHR 7 ×10 –1 ), major vas-
ular invasion (logHR 3 ×10 –1 ), and extrahepatic disease (logHR
 ×10 –1 ). Using these factors, patients could be stratiﬁed into sep-
rate risk categories—low risk (logHR 0–4 ×10 –1 ) versus high risk
logHR > 4 ×10 –1 )—that had different OS ( P < .001; Fig. 3 ). The C
ndex of the prediction model for low- versus high-risk patients
as 0.62 (standard error: 0.021). Importantly, when NLR (logHR
 ×10 –1 ) was added to the prognostic model, the discriminatory
bility of the model improved (C index 0.71, standard error: 0.024).
n particular, low-risk patients with NLR ≥5 had a worse OS versus
ow-risk patients with NRL < 5 ( P = .040) ( Fig. 4 ). In contrast, NLR
tatus did not affect the prognosis of patients who already had a
igh-risk proﬁle (median survival: NRL < 5, 18.7 months, 95% CI:
4.6–22.7 vs NLR ≥5, 20.9 months, 95% CI: 1.8–40.0) ( P = .998). 
iscussion 
The incidence of ICC, a rare malignant liver tumor that ac-
ounts for 5%–10% of primary liver carcinomas, has been increas-
ng over the last several decades from 3.2 per 1,0 0 0,0 0 0 in 1975
o 8.5 per 1,0 0 0,0 0 0 in 2010, particularly in the Western coun-
ries. 26–28 ICC is a malignancy associated with high mortality, and
ven patients undergoing curative intent surgery have a 5-year ac-
uarial survival of only 30%–35%. 8 Some investigators have tried
o identify preoperative factors to stratify the long-term outcome
f patients with ICC. 11,14 To this end, factors such as tumor num-
er, tumor size, major vascular invasion, and suspicious lymph
ode metastases have been proposed in staging schemes and
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Fig. 1. Overall survival stratiﬁed by neutrophil-to-lymphocyte ratio (NLR) ( P = .001). 














N  omograms to stratify patients with regard to OS. 11,14 These previ-
us models have largely included only tumor-speciﬁc clinicopatho-
ogic factors, many of which can only be deﬁnitively determined on
ostoperative pathologic examination. More recently, other investi-
ators have suggested the inclusion of preoperative tumor-speciﬁc
iomarkers such as CEA or CA 19-9 to help anticipate postoper-
tive prognosis. 4,29 , 30 The present study was important because—nlike most previous studies—we focused on non–tumor-speciﬁc
nﬂammatory biomarkers. Speciﬁcally, we deﬁned the prognostic
mpact of NLR and PLR among patients undergoing curative-intent
esection of ICC. Although PLR was not associated with progno-
is, an elevated NLR was independently associated with poor OS
mong patients with ICC undergoing resection. In addition, when
LR was added to a prognostic model that included traditional
416 S. Buettner et al. / Surgery 164 (2018) 411–418 
Fig. 3. Overall survival stratiﬁed by low-risk (log-hazard ratio [logHR] 0–4) and high-risk factors (logHR > 4) ( P < .001). 
Fig. 4. Low-risk patients stratiﬁed by neutrophil-to-lymphocyte ratio (NLR) status ( P = .040). 
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Table IV 
Univariable and multivariable analysis of overall survival. 
Univariable Multivariable 
Characteristic HR 95% CI P HR 95% CI P 
Age, y 1.00 0.99–1.01 .695 
Gender 
Male Ref — —
Female 0.96 0.80–1.14 .628 
ASA III/IV 1.22 1.01–1.47 .038 
BMI 1.02 1.00–1.03 .095 
Hepatitis B 0.98 0.76–1.26 .889 
Hepatitis C 1.16 0.65–2.08 .607 
Preoperative suspicious lymph nodes 1.64 1.32–2.04 < .001 1.38 1.10–1.74 .006 
Bilobar location 1.45 1.17–1.79 < .001 
Tumor size (cm) 1.07 1.04–1.09 < .001 1.04 1.02–1.07 < .001 
No. of lesions 1.25 1.17–1.33 < .001 1.15 1.08–1.24 < .001 
Major vascular invasion 1.66 1.25–2.19 < .001 1.38 1.03–1.85 .030 
Serum GGT 1.00 1.00–1.00 .001 
Serum CA 19-9 1.00 1.00–1.00 .861 
Serum CEA 1.00 1.00–1.00 < .001 1.00 1.00–1.00 .012 
Serum total bilirubin 1.00 0.99–1.01 .822 
Preoperative jaundice 1.88 1.45–2.43 < .001 1.58 1.20–2.08 .002 
Cirrhosis 1.11 0.85–1.45 .439 
Extrahepatic disease 2.79 1.74–4.48 < .001 2.32 1.38–3.91 .001 
NLR 1.04 1.02–1.07 < .001 1.04 1.01–1.07 .002 
PLR 1.00 1.00–1.00 .085 
ASA, American Society of Anesthesiologists; BMI, body mass index; CA, cancer antigen; CEA, carcinoem- 
bryonic antigen; CI, conﬁdence interval; GGT, γ -glutamyltransferase; HR, hazard ratio; NLR, neutrophil- 












































































t  umor-speciﬁc factors, the discriminatory ability of the model im-
roved. 
Several previous studies have evaluated the prognostic role of
LR and PLR in different diseases. 20–25 A recent meta-analysis re-
orted a strong correlation between NLR and poor postoperative
utcomes for biliary tract cancers, 31 whereas other studies have
uggested that PLR may have a prognostic role among patients
ith colorectal, hepatocellular, pancreatic, and ovarian cancers. 32,33 
n addition, a recent study by our own group found that ele-
ated preoperative NLR and PLR levels were associated with long-
erm prognosis among patients with pancreatic and secondary
etastatic cancers of the liver. 22 The present study expanded on
ast work because the prognostic impact of NLR and PLR among
atients undergoing curative intent surgery for ICC had not been
 speciﬁc topic of previous inquiry. Of note, elevated NLR was in-
eed an independent predictor of poor overall survival among pa-
ients with ICC who underwent curative intent resection. Specif-
cally, patients with an NLR ≥5 had a median survival that was
ess than half that of patients who had an NLR < 5 (21.9 months vs
7.1 months, respectively; P = .001). These ﬁndings were consistent
ith the results from our previous work that investigated patients
ith pancreas and secondary liver metastasis. 22 In fact, in that se-
ies, the proportion of patients with NLR ≥5 who survived to 5
ears was roughly half that compared with patients who had an
LR ≥5 (29.2% vs 61.8%, respectively; P = .01). However, unlike pre-
ious data that suggested PLR also affected prognosis, we failed to
nd an association of elevated PLR with OS among patients under-
oing resection of ICC. 
There is a biological rationale for the association of NLR with
S. Neutrophilic granulocytes are the most common type of white
lood cells and the most important factor in the innate immune
ystem. 18 The number of neutrophils is upregulated in the pres-
nce of malignancy, and neutrophil-mediated inﬂammation plays
n important role in tumorigenesis and tumor progression. 17,18 
lthough the inﬂuence of neutrophils is multifaceted and can
ither enhance or slow tumor growth, most published clinical
tudies support the notion that neutrophils promote cancer pro-
ression. 17–19 Furthermore, neutrophilia can inhibit the adaptivemmune response and may decrease the effect of activated lym-
hocytes. 34,35 The NLR, as a measure of this effect, can therefore
e related to a worse prognosis in several solid tumors. 19–25 
he present study conﬁrmed the prognostic role of NLR among
atients undergoing curative intent surgery for ICC. In contrast,
LR was not associated with survival. Platelets are also part of the
umor inﬂammatory response and thrombocytosis can be related
o tumor growth, invasion, and angiogenesis. 32,36 In addition,
hrombocytosis has been suggested to protect tumor cells from
ell-mediated lysis and facilitates tumor spreading. 37 Interestingly,
n the present study, PLR elevation was not associated with a more
ggressive tumor phenotype because there were few clinicopatho-
ogic differences among patients with a PLR < 190 vs PLR ≥190.
lthough patients with a PLR ≥190 were more likely to have had
 resection with microscopically positive margins, PLR was not
ssociated with long-term prognosis on multivariable analysis. 
Although any single factor may be associated with survival, the
ombination of clinicopathologic variables into a single “score” or
omogram may allow for better prognostic stratiﬁcation. Hyder et
l 11 created a nomogram based on age at diagnosis (HR: 1.31),
umor size (HR: 1.50), multiple tumors (HR: 1.58), cirrhosis (HR:
.51), lymph node metastasis (HR: 1.78), and macrovascular inva-
ion (HR: 2.10) (all P < .001). 11 On the basis of these factors, a
omogram was created to predict survival of ICC after resection
hat revealed good predictive abilities. Similarly, in the present
tudy, several preoperative factors (eg, suspicious lymph nodes,
EA, jaundice, tumor size and number, major vascular invasion)
hat were signiﬁcant on multivariable analysis were included in a
core to predict long-term prognosis. Using these factors, patients
ould be stratiﬁed according to prognosis with a good to moderate
 index. Of interest, the predictive model improved markedly when
LR was included as one of the prognostic variables (C index 0.71).
hese data suggest that the combination of tumor-speciﬁc factors
eg, size, number, vascular invasion) with information about host
esponse (eg, NLR) may improve the ability to estimate long-term
rognosis of patients with ICC undergoing surgical resection. 
The present study should be considered in light of several limi-
ations. As with any retrospective analysis, selection bias may have




























































































 affected which patients were offered surgical resection. In turn, pa-
tients with more aggressive oncologic features may be dispropor-
tionately under-represented because these patients were less likely
to be offered surgery. Differences in patient selection and surgi-
cal technique, as well as adjuvant treatment among different cen-
ters, was also possible; however, the multi-institutional nature of
the study did allow for a larger sample size and generalizability.
Finally, the lack association of PLR with prognosis may have been
due to a type II error, although this seems unlikely because roughly
the same number of patients had an elevated PLR as did NLR. 
In conclusion, long-term outcomes of patients after curative in-
tent surgery were relatively poor, with a 5-year survival of only
about 40%. Prognosis was associated with several preoperative
tumor-speciﬁc factors, such as tumor size and number and major
vascular invasion. After controlling for these tumor-speciﬁc factors,
host-related factors such as elevation in NLR was independently
associated with worse long-term outcomes. In fact, the median
survival of patients with an elevated NLR was roughly half that
of patients with a normal or low NLR. In addition, the inclusion
of NLR into a multivariable preoperative model increased the abil-
ity to estimate OS. Future staging schemes for ICC should consider
the addition of host-related factors such as NLR to tumor-speciﬁc
factors to improve the ability to predict long-term outcomes. 
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